MedWatch

Analysts sow doubts about Ambu's projections

According to analysts, the chances of another downgrade from Ambu have gone up. Should that happen, a stock issuance might be necessary, J.P. Morgan says.

Photo: PR / Ambu

Following Ambu’s first quarterly report entailing a very cautious prognosis, analysts and investors have started to worry that Ambu is going to disappoint, reports Danish business daily Børsen.

”The world has gotten more uncertain since January. Logistics chains are more uncertain, and raw material prices have gone further up, so the likelihood of downgrade number four within one year has significantly increased,” says Niels Granholm-Leth, head of equity research at Carnegie Investment Bank, on Ambu’s guidance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs